49 completed. 49 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 49 | Completed 49 |
| Phase 2 | 1 | Completed 1 |
Follow Open-Angle Glaucoma: new trials by email Literature Review of Open-Angle Glaucoma trials Research Report on Open-Angle Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma XEN45 (Glaucoma Gel Stent) - Open-Angle Glaucoma | Phase 3 | Completed | AbbVie | 74 | 2022-07-22 | 2026-02-27 |
| A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension Bimatoprost SR, LUMIGAN - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | AbbVie | 37 | 2020-06-11 | 2023-06-08 |
| Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Bimatoprost SR, Standard of Care - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | AbbVie | 455 | 2019-03-27 | 2026-07-15 |
| Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension Bimatoprost (SR) - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | AbbVie | 515 | 2019-02-28 | 2025-08-19 |
| Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005% - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 750 | 2016-02-01 | 2019-05-21 |
| Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005% - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 718 | 2015-09-18 | 2019-06-04 |
| Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 708 | 2015-09-01 | 2018-04-06 |
| Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, Brinzolamide 10 mg/mL eye drops, suspension, Brimonidine 2 mg/mL eye drops, solution - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 493 | 2015-04-14 | 2018-07-02 |
| Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Aerie Pharmaceuticals | 756 | 2014-07-01 | 2018-04-06 |
| Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Aerie Pharmaceuticals | 411 | 2014-07-01 | 2018-04-13 |
| Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension BOL-303259-X, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Bausch & Lomb Incorporated | 420 | 2013-01-31 | 2018-11-07 |
| Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension BOL-303259-X, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Bausch & Lomb Incorporated | 420 | 2013-01-01 | 2018-11-21 |
| Travoprost 3-Month Safety and Efficacy Study Travoprost ophthalmic solution, 0.003%, Travoprost ophthalmic solution, 0.004% - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 1099 | 2011-11-01 | 2013-10-18 |
| Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, Vehicle, Brinzolamide 1% ophthalmic suspension - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 1184 | 2011-05-01 | 2014-04-07 |
| Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Brimonidine tartrate 0.2% ophthalmic solution - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 771 | 2011-05-01 | 2014-03-06 |
| Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2% Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2% - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 1062 | 2011-03-01 | 2013-07-04 |
| Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations Timolol and Tafluprost, Fixed Dose Combination of tafluprost and timolol - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Santen Oy | 401 | 2011-03-01 | 2012-06-08 |
| Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2% Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2% - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 1001 | 2011-02-01 | 2013-05-21 |
| Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies Timolol/ FDC/ Placebo/ Tafluprost - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Santen Oy | 600 | 2011-02-01 | 2013-03-13 |
| Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Timolol 0.5% ophthalmic solution - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 328 | 2010-11-01 | 2014-04-10 |
Showing 20 of 49. Sign in to see all of them.
Glaucoma, Open-Angle (49) · Ocular Hypertension (42) · Glaucoma (17) · Hypertension (9) · Cataract (2)
Eye Diseases (49) · Glaucoma (32) · Cardiovascular Diseases (9) · Vascular Diseases (9) · Ocular Hypertension (7) · Lens Diseases (2)
Timolol (13) · Ophthalmic Solutions (12) · Travoprost (12) · brinzolamide (8) · Latanoprost (6) · Brimonidine Tartrate (5) · netarsudil (5) · Duotrav (4) · tafluprost (4) · BID protein, human (3) · Solutions (3) · Suspensions (3) · BOL 303259-X (2) · Bimatoprost (2) · Cataract Extraction (2)
Alcon Research (26) · Aerie Pharmaceuticals (5) · Santen Oy (5) · AbbVie (4) · Allergan (2) · Bausch & Lomb Incorporated (2) · Glaukos Corporation (2) · Merck Sharp & Dohme LLC (1) · National Eye Institute (NEI) (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)
United States (20) · Germany (4) · Finland (3) · Argentina (2) · Australia (2) · Czechia (2) · Denmark (2) · Hungary (2) · Italy (2) · New Zealand (2) · Poland (2) · Russia (2) · South Africa (2) · United Kingdom (2) · Belgium (1)
Theresa Heah, MD (3) · Auli Ropo, M.D. (2) · James Teague, BS, Sr. Clinical Manager (2) · Jason Vittitow (2) · Pamela Smith, B.S. (2) · Theresa Heah, MD, MBA (2) · Clemens Vass, M.D. (1) · Eva Ruzickova, M.D. (1) · Evgeniy Egorov, Professor (1) · Guna Laganovska, M.D. (1) · Hannu Uusitalo, M.D., Prof. (1) · Hannu Uusitalo, Professor (1)
PMID 29194198, PMID 32166538, PMID 18414108, PMID 18538406, PMID 19365194, PMID 20828829, PMID 22310086, PMID 22814041, PMID 23579344, PMID 25430900, PMID 25447269, PMID 26875002, PMID 27210275, PMID 31981106, PMID 33250082, PMID 37343625, PMID 39985740
2018 (2), 2023 (1)